Treatment of iron deficiency anemia in adults
Stanley L Schrier, MD
Michael Auerbach, MD, FACP
Section Editor:
William C Mentzer, MD
Deputy Editor:
Jennifer S Tirnauer, MD
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Feb 2018. | This topic last updated: Mar 09, 2018.

INTRODUCTION — More than a quarter of the world's population is anemic, with about one-half of the burden from iron deficiency. The prevention and treatment of iron deficiency is a major public health goal, especially in women, children, and individuals in low-income countries.

Challenges in the treatment of iron deficiency include finding and addressing the underlying cause and the selection of an iron replacement product that meets the needs of the patient.

This topic review discusses the management of iron deficiency anemia in adults. The causes and diagnosis of iron deficiency in adults are presented separately. (See "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults".)

Separate topic reviews also discuss treatment of iron deficiency in specific populations:

Infants and young children – (see "Iron deficiency in infants and children <12 years: Treatment")

Adolescents – (see "Iron requirements and iron deficiency in adolescents")

Pregnancy – (see "Nutrition in pregnancy")

Older adults – (see "Anemia in the older adult", section on 'Iron deficiency anemia')

Chronic kidney disease – (see "Treatment of iron deficiency in hemodialysis patients")

Inflammatory bowel disease – (see "Nutrient deficiencies in inflammatory bowel disease", section on 'Iron')

Bariatric surgery – (see "Bariatric surgery: Postoperative nutritional management")

Malignancy – (see "Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Iron monitoring and supplementation')

Prevention of iron deficiency in certain at-risk populations is also presented in separate reviews. (See "Introducing solid foods and vitamin and mineral supplementation during infancy" and "Persistent diarrhea in children in resource-limited countries".)


Indications for treatment — Regardless of the presence of symptoms, all patients with iron deficiency anemia and most patients with iron deficiency without anemia should be treated [1]. The rationale is that there is risk for further organ damage/ischemia and progression of anemia unless the underlying cause of the deficiency is addressed and adequate iron stores are replenished. An exception is when iron depletion is used therapeutically (eg, porphyria cutanea tarda, polycythemia vera). (See "Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis", section on 'Phlebotomy' and 'Myeloproliferative syndromes' below.)

Anemia — Some patients with iron deficiency anemia will be asymptomatic; others will have symptoms that may include the following:

Symptoms of anemia, which may include weakness, headache, decreased exercise tolerance, fatigue, irritability, or depression

Neurodevelopmental delay (children)

Pica and pagophagia (ice craving)

Beeturia (reddish urine after eating beets)

Restless legs syndrome

Similar symptoms, especially fatigue and exercise intolerance, can also be present in individuals who are iron deficient but not anemic. These symptoms and their pathophysiology are discussed in detail separately. (See "Iron deficiency in infants and children <12 years: Screening, prevention, clinical manifestations, and diagnosis", section on 'Clinical manifestations of IDA' and "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Clinical manifestations'.)

When treatment is indicated, the usual approach is repletion of iron. Blood transfusion should not be used a treatment for iron deficiency unless the individual has severe anemia or hemodynamic instability. (See 'Severe/life-threatening anemia' below.)

Iron deficiency without anemia — Some individuals with reduced or absent iron stores who have not yet developed anemia may have symptoms such as fatigue or reduced exercise tolerance.

The approach to therapy is individualized according to etiology and severity of iron deficiency. We replace iron stores in most patients who have iron deficiency without anemia, with the rationale that this treatment is likely to improve symptoms, and failure to treat is likely eventually to result in anemia. These patients are often referred to the hematologist after iron studies reveal iron deficiency as part of screening laboratory tests performed to evaluate fatigue or unexplained microcytosis.

The benefit of iron replacement for iron deficiency-associated fatigue without anemia has been demonstrated in several small trials and observational studies:

A trial randomly assigned 90 non-anemic premenopausal women with fatigue, serum ferritin ≤50 ng/mL, and hemoglobin ≥12.0 g/dL to receive a cumulative dose of 800 mg of intravenous (IV) iron or placebo over two weeks [2]. Six weeks after treatment initiation, fatigue was improved in the IV iron arm (decrease of 1.1 versus 0.7 on a 10-point scale, from a baseline of 4.5 in both groups). The effect was more pronounced in those with a baseline serum ferritin ≤15 ng/dL. Benefits of iron supplementation persisted at 12 weeks. Adverse events were greater in the IV iron group (21 versus 9 percent), but none were considered serious. As expected, the IV iron group had increased ferritin (mean increase, 98 ng/mL) and the placebo group did not. Observational studies have also reported improvement in symptoms in non-anemic premenopausal women with low ferritin who were treated with IV iron [3].

Three trials that randomly assigned groups of non-anemic women with low ferritin to oral iron supplementation (typically 80 mg of elemental iron daily) versus placebo or a high-iron diet all reported improvement in fatigue with oral iron [4-6]. The trial that used dietary iron as a comparator also found improvement with dietary iron, but mean increases in ferritin were greater in the supplement group [4].

Additional trials in runners and blood donors have demonstrated that iron repletion can improve athletic performance, sleep disturbance, and fingernail breakage [7-9]. (See 'Athletes' below.)

These data are supportive of the above recommendation that iron should be repleted in those with iron deficiency without anemia. The importance of finding the source of blood loss or iron loss also applies in these individuals. (See 'Source of deficiency/blood loss' below.)

Routine iron administration to individuals without iron deficiency is not advised. Rarely, some experts will treat a patient who has symptoms compatible with iron deficiency (eg, restless legs syndrome) without overt laboratory evidence of reduced iron stores if all other interventions have been exhausted. (See "Treatment of restless legs syndrome and periodic limb movement disorder in adults", section on 'Iron replacement'.)

Source of deficiency/blood loss — Treatment of iron deficiency and iron deficiency anemia involves more than simply replacing iron. In all patients, the cause of iron deficiency must be identified and addressed. This is especially true for men and non-menstruating women, in whom new onset iron deficiency is strongly suggestive of blood loss from an occult gastrointestinal malignancy or other bleeding lesion.

Dietary deficiency – Infants and young children may not receive adequate dietary iron if they are exclusively given cow’s milk, breast milk, or formula that is not supplemented with iron. For adults in resource-rich countries, dietary iron deficiency is exceedingly rare because of iron availability in many meats (as heme iron) and vegetables (as non-heme iron), along with routine supplementation of grains with iron. (See "Iron deficiency in infants and children <12 years: Screening, prevention, clinical manifestations, and diagnosis".)

Impaired absorption – Certain gastrointestinal conditions may lead to iron deficiency due to impaired absorption. Examples include inflammatory bowel disease and gastric bypass surgery. (See "Bariatric surgery: Postoperative nutritional management" and "Nutrient deficiencies in inflammatory bowel disease".)

Pregnancy – Pregnancy results in increased iron requirements for fetal/placental development and to increase maternal red blood cell mass. Total iron loss associated with pregnancy and lactation is approximately 1000 mg. Iron deficiency may be seen, especially in women with multiple pregnancies and/or borderline iron status prior to pregnancy. (See "Nutrition in pregnancy", section on 'Iron' and "Maternal adaptations to pregnancy: Hematologic changes", section on 'Dilutional anemia'.)

Bleeding – Bleeding is the most common cause of iron deficiency in adults. (See "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults".)

Menstruating women – Normal menstruation does not lead to iron deficiency. However, abnormal uterine bleeding/menorrhagia has been reported to cause iron deficiency anemia in one-fifth to two-thirds of affected women. Approaches to determining the site and cause of bleeding are presented separately. (See "Management of abnormal uterine bleeding" and "Abnormal uterine bleeding in adolescents: Evaluation and approach to diagnosis", section on 'Approach to diagnosis'.)

Other known bleeding site – Other known bleeding sites include gastrointestinal lesions, telangiectasias associated with hereditary hemorrhagic telangiectasia (HHT, also called Osler-Weber-Rendu syndrome), and renal pulmonary syndromes. Specific lesions may be amenable to surgical or medical intervention in some cases. (See "Causes of upper gastrointestinal bleeding in adults" and "Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)" and "The diffuse alveolar hemorrhage syndromes".)

Adults without an obvious source of blood loss – Adults without an obvious source of blood loss must be evaluated for occult gastrointestinal malignancy unless there is a clear reason not to do so. This is especially true for individuals >50 years of age, non-menstruating women, and those at increased risk of colorectal cancer based on family history or other risk factors. (See "Colorectal cancer: Epidemiology, risk factors, and protective factors", section on 'Risk factors'.)


Severe/life-threatening anemia — Patients with severe, severely symptomatic (eg, with symptoms of myocardial ischemia), or life-threatening anemia should be treated with red blood cell (RBC) transfusion because correction of iron deficiency anemia using iron replacement requires time for iron administration and incorporation into RBCs.

RBC transfusion can be life saving for the patient who is hemodynamically unstable due to active bleeding, and/or when evidence of end-organ ischemia secondary to severe anemia is present. The following may be expected for each unit of packed RBCs transfused to an adult, as long as there is not ongoing bleeding:

Total volume – 300 mL

Volume of RBCs – approximately 200 mL

Iron – 200 mg (in the form of hemoglobin)

Increase in hemoglobin – approximately 1 g/dL

Increase in hematocrit – approximately 3 percentage points

Once the patient is stabilized with transfusion, the need for additional iron supplementation can be determined and evaluation for the cause can be pursued.

Infants/young children — (See "Iron deficiency in infants and children <12 years: Treatment".)

Adolescents — (See "Iron requirements and iron deficiency in adolescents", section on 'Treatment'.)

Pregnancy — Iron requirements increase during pregnancy, to accommodate fetal and placental needs, expansion of the maternal RBC mass, and blood loss during delivery [10]. (See "Maternal adaptations to pregnancy: Hematologic changes", section on 'Red blood cells'.)

The adverse maternal and fetal effects of iron deficiency anemia in pregnancy were illustrated in a retrospective review of 75,660 term singleton deliveries at a single institution, 7977 of which (11 percent) were associated with maternal iron deficiency anemia at presentation for delivery [11]. Compared with controls, women with iron deficiency anemia were at increased risk of transfusion (odds ratio [OR] 5.48; 95% CI 4.57-6.58), preterm delivery (OR 1.54; 95% CI 1.36-1.76), and cesarean delivery (OR 1.30; 95% CI 1.13-1.49). Increased adverse fetal outcomes included 5-minute Apgar <7 (OR 2.21; 95% CI 1.84-2.64), intensive care admission (OR 1.28; 95% CI 1.04-1.57), macrosomia (OR 1.23; 95% CI 1.12-1.35), and large for gestational age (OR 1.29; 95% CI 1.20-1.39). Anemic women were also more likely to be younger and multiparous.

We often use intravenous (IV) iron to treat iron deficiency anemia in pregnant women in our practice, in order to avoid the gastrointestinal side effects of oral iron; these may be compounded by pregnancy-associated bloating and constipation due to high progesterone levels and the pressure of the gravid uterus on the rectum. We routinely administer 1000 mg of low molecular weight iron dextran (LMW ID) in one hour to iron deficient pregnant women in the second or third trimester, whether or not they are intolerant of oral iron [12-14]. The efficacy of this approach was demonstrated in a study in which 73 women in the second or third trimester of pregnancy were treated with LMW ID [15]. The mean hemoglobin level increased from 9.7 to 10.8 g/dL and the mean ferritin increased from 15 to 126 ng/mL. Six individuals had minor infusion reactions that resolved spontaneously after interruption of the infusion for 15 to 30 minutes, after which the remainder of the dose was given after premedication with methylprednisolone (see 'Allergic and infusion reactions' below). We have not observed any serious adverse effects in over 2000 pregnant patients treated. (See 'Intravenous iron' below.)

The efficacy of this approach was demonstrated in a series of 189 consecutive pregnant women with hemoglobin <10.5 g/dL who were treated with 1000 mg of IV LMW ID during the second or third trimester of pregnancy [13]. The full dose was administered over one hour after a test dose and without premedications, with the exception of individuals with a history of asthma or multiple drug allergies who were given 125 mg of IV methylprednisolone. There were no serious adverse events, and hemoglobin levels increased by a mean of 1.4 g/dL. Four patients (2 percent) had a transient infusion reaction (sneezing, congestion, myalgias) treated with brief interruption of the infusion (10 to 15 minutes) and one dose of methylprednisolone, followed by administration of the remainder of the dose.

However, not all women will have access to (or choose to receive) IV iron. For these individuals, anemia due to iron deficiency can be treated by adding an oral iron supplement to the standard prenatal vitamin, as discussed separately (see "Nutrition in pregnancy", section on 'Iron'). Approaches to reducing the gastrointestinal toxicities of oral iron are presented below. (See 'Strategies to improve tolerability' below.)

A 2011 Cochrane review of randomized trials for the treatment of iron deficiency in pregnancy found that iron supplementation was effective in treating maternal anemia [16]. Some studies showed better improvements in anemia with parenteral versus oral iron and others did not. Fetal outcomes were similar with oral versus IV iron repletion, but fetal outcomes with iron supplementation versus placebo were not evaluated [16]. Oral iron was associated with increased frequency of abdominal pain, cramps, nausea, vomiting, diarrhea, constipation, itching and rash; intramuscular iron was associated with pain at the injection site. From the standpoint of the developing fetus, iron repletion, as well as a more liberal use of IV iron in pregnancy, will likely minimize the chance that the neonate of an iron-deficient woman will also be iron deficient, especially in view of evidence that iron-deficient neonates have delayed growth and development and an increase in behavioral problems that persist up to 10 years after iron repletion [16,17].

The safety and efficacy of IV iron in pregnancy has been illustrated by a number of small trials and case series that have found IV iron to be as good or better than oral iron without serious adverse events; however, most of these were too small to allow extensive safety evaluation [12,13,18-24]. As noted above, we reserve IV iron for the second and third trimesters, as safety during the first trimester has not been established.

If iron was not repleted (or incompletely repleted) during pregnancy, it may be administered postpartum. However, delaying iron repletion until after delivery is not advised, because this practice is likely to leave the infant iron deficient.

Older adults — Older individuals may become iron deficient for a number of reasons. As noted above, a search for the cause of new onset iron deficiency is mandatory for all older individuals for whom a new underlying lesion would be treated. (See 'Source of deficiency/blood loss' above.)

Older individuals may also have a higher incidence of intolerance to oral iron supplementation and reduced absorption of oral iron, especially if they are taking antacids or have impaired gastric acid production. Lower doses of iron may be effective and at the same time cause less gastrointestinal toxicity. This was demonstrated in a randomized trial that compared different doses of oral iron (15, 50, or 150 mg daily) in 90 hospitalized individuals who were over the age of 80 years and had iron deficiency anemia (hemoglobin 8 to 11.9 g/dL; ferritin <40 ng/mL) [25]. All doses were effective, and improvements in hemoglobin level were comparable at 60 days; there was a significantly lower rate of reported gastrointestinal side effects with the lowest dose of oral iron. As noted below, we use dosing on alternate days rather than every day. As an example, a dose of oral iron elixir may be given on Monday, Wednesday, and Friday. (See 'Dosing and administration (oral iron)' below and 'Strategies to improve tolerability' below.)

In that oral iron is unlikely to be of benefit, even at reduced doses in this population, we have a lower threshold for switching to IV iron if oral iron is poorly tolerated. (See 'Uses for IV iron' below.)

Inflammatory bowel disease — Iron deficiency and iron deficiency anemia may affect a significant proportion of individuals with inflammatory bowel disease (IBD), especially those with ulcerative colitis. (See "Nutrient deficiencies in inflammatory bowel disease".)

We favor IV iron for individuals with IBD, especially those with significant disease activity or more severe anemia, for the following reasons [26,27]:

Many individuals with IBD have severe intolerance to oral iron preparations, which may also worsen IBD disease activity. In a retrospective review of 277 individuals with IBD who were treated with oral iron, intolerance to therapy was seen in one-fourth [28]. In a series of 19 individuals with IBD who were randomly assigned to receive IV iron sucrose or oral ferrous fumarate, the oral iron was associated with increased disease activity, worse wellbeing score, and increased abdominal pain [29].

Individuals with IBD may have ongoing inflammation and/or malabsorption that may interfere with iron absorption, and IV iron is better able than oral iron to partially overcome the iron-restricted erythropoiesis associated with inflammation.

Use of IV rather than oral iron may be associated with better preservation of microbial diversity in the gut [30].

Numerous studies in the United States and other countries have demonstrated the safety and efficacy of various IV iron preparations in these patients [31-34]. This practice is consistent with recommendations from several expert panels [35-38]. In Europe, IV iron is standard frontline therapy for IBD-associated iron deficiency [27]. Of the IV iron formulations, iron sucrose has been extensively studied in IBD, although ferric carboxymaltose, LMW iron dextran, iron isomaltoside and ferumoxytol have all been shown to be effective [29,34,39-41].

Oral iron may be used in individuals for whom IBD disease activity and anemia are mild, those who wish to avoid the costs and inconvenience associated with IV iron, those who wish to determine their tolerance of oral iron before using IV iron, and those for whom intolerance of oral iron is not a concern.

Gastrointestinal/bariatric surgery — Gastric bypass and other gastric surgeries, such as partial resection for ulcer disease or gastrectomy for gastric cancer, increase the risk of iron deficiency, as well as numerous other vitamin and mineral deficiencies. (See "Nutrient deficiencies in inflammatory bowel disease", section on 'Iron'.)

The mechanism is mainly due to the removal or bypass of intestinal tissues needed for nutrient absorption, particularly the duodenum, the richest source of ferroportin. For patients who have undergone gastric resection, reduced gastric acid production further contributes. In the stomach, iron is normally conjugated to compounds (eg, amino acids, sugars, vitamin C) that protect it from conversion to ferric hydroxide (rust) [14]. Gastrectomy may also be associated with perioperative blood loss.

We prefer IV rather than oral iron for most patients who have undergone gastric resection, Roux-en-Y, biliopancreatic diversion, or similar procedures, as it ensures adequate delivery and avoids gastrointestinal toxicities, which may be especially burdensome in these patients. Some patients, especially those having undergone minimally invasive procedures such as gastric banding, may tolerate oral iron. However, multiple gastrointestinal perturbations are often present in this population, and IV iron may simplify care. For those for whom IV iron is not available, additional strategies for improving absorption and tolerability may be required. (See 'Strategies to improve tolerability' below.)

We also prefer IV rather than oral iron for most patients who have anemia following gastrectomy. The efficacy of IV iron was demonstrated in a trial that randomly assigned 454 patients who underwent gastrectomy for gastric cancer and had anemia (hemoglobin from 7 to 10 g/dL) within the week after the surgery to receive IV iron (ferric carboxymaltose, 1000 mg if body weight was ≥50 kg; 500 mg if body weight was <50 kg) or placebo [42]. Compared with the placebo group, the IV iron group was less likely to require additional treatment for anemia (oral iron in 4.1 versus 0 percent; transfusions in 1.8 versus 1.4 percent). There were no serious adverse events (mild to moderate urticaria and injection site reactions in 10 percent), and quality of life was similar between the two groups.

Other surgeries/perioperative — Perioperative patients may have anemia from blood loss, and others may have undiagnosed iron deficiency that becomes apparent in the perioperative evaluation. Perioperative iron administration has been demonstrated to reduce the degree of anemia and in some cases to reduce transfusions in a variety of other types of surgery. The reduction in transfusions appears to be greatest in those with preoperative anemia, and we would administer IV iron to individuals with preoperative anemia if the estimated surgical blood loss is likely to be significant. In a trial that randomly assigned 201 patients undergoing elective surgery who had anemia and evidence of iron deficiency (ferritin <100 ng/mL or transferrin saturation <20 percent) to receive standard care or standard care plus IV ferric carboxymaltose, the hemoglobin level four weeks postoperatively was greater in the IV iron group (12 versus 13 g/dL) [43]. The proportion who were transfused was also lower in the IV iron group (5 versus 1 percent), although this may have been affected by knowledge of the assignment to IV iron.

Other trials in specific surgical populations have also been conducted:

Cardiac – In a 2015 trial, 60 non-anemic patients undergoing coronary artery bypass grafting (CABG) and/or valve replacement were randomly assigned to receive a single dose of 1000 mg IV iron isomaltoside or placebo on the day before or the day of surgery [44]. Both groups had a postoperative decrease in hemoglobin level, but compared with the placebo group, the IV iron group had a smaller decrease (mean hemoglobin level at four weeks, 11.6 versus 12.4 g/dL). There was a trend toward fewer transfusions in the IV iron group that did not reach statistical significance (6 versus 4 transfusions [20 versus 13 percent]) and a similar rate of serious adverse events in the placebo and iron groups (9 versus 8 [30 versus 27 percent]).

Abdominal surgery – In a 2016 trial, 72 patients with anemia prior to major abdominal surgery (eg, colectomy, hysterectomy) were randomly assigned to receive a single preoperative dose of ferric carboxymaltose (15 mg/kg, maximum 1000 mg) prior to surgery, with additional doses depending on surgical blood loss or usual care [45]. Compared with usual care, the IV iron group had fewer transfusions (17 versus 5 [53 versus 13 percent]), and a higher hemoglobin level at four weeks (12.2 versus 11.1 g/dL); there were no serious adverse events.

Orthopedic surgery – In a 2011 trial, 200 patients undergoing hip fracture surgery were randomly assigned to receive iron sucrose (600 mg divided into three doses, the first preoperatively) or usual care [46]. Compared with usual care, the IV iron group had a trend towards fewer transfusions that did not reach statistical significance (41 versus 33 percent). In a 2013 meta-analysis of observational studies that included 2547 patients undergoing hip or arthroscopic surgery, perioperative iron administration, with or without erythropoietin, was associated with a lower rate of transfusions [47].

Various types of surgery – In a 2016 trial, 201 patients who had postoperative anemia following a number of elective surgeries (orthopedic, genitourinary, abdominal) were randomly assigned to receive a single dose of ferric carboxymaltose (1000 mg) or usual care [43]. Compared with the usual care group, the IV iron group received fewer transfusions (5 versus 1 percent) and had a higher hemoglobin level at four weeks (12.2 versus 13.0 g/dL).

Helicobacter and gastritis — Helicobacter pylori infection, autoimmune gastritis, and celiac disease are chronic conditions of which the patient may be unaware. These conditions are common causes of iron deficiency in individuals without a source of blood loss, and they can interfere with oral iron absorption [48]. Individuals who have a blunted or incomplete response to oral iron therapy may be tested for these conditions, as discussed below. (See 'Approaches to lack of response' below.)

Details of the evaluation and treatment for these conditions are presented separately:

H. pylori – (See "Indications and diagnostic tests for Helicobacter pylori infection" and "Treatment regimens for Helicobacter pylori".)

Autoimmune gastritis – (See "Metaplastic (chronic) atrophic gastritis".)

Celiac disease – (See "Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults" and "Diagnosis of celiac disease in adults" and "Management of celiac disease in adults".)

Chronic kidney disease — IV iron is the current standard in both dialysis- and nondialysis-associated chronic kidney disease (CKD). The rationale includes a number of biological and practical aspects of CKD, including impaired oral absorption, frequent use of calcium-containing salts and antacids, ongoing blood loss, synergism with erythropoiesis-stimulating agents (ESAs), and frequent visits and established IV access in those undergoing hemodialysis. This subject, and dosing for patients with CKD, is discussed in detail separately. (See "Treatment of iron deficiency in nondialysis chronic kidney disease (CKD) patients", section on 'Treatment' and "Treatment of iron deficiency in hemodialysis patients", section on 'Dosing and administration'.)

Cancer — There are numerous causes of anemia in patients with cancer, including chronic inflammation, impaired absorption of nutrients, hemolysis, and iron deficiency, often caused by bleeding. (See "Hematologic complications of malignancy: Anemia and bleeding".)

Effective therapies for cancer-associated anemia include treatment of the malignancy, blood transfusion, and erythropoiesis-stimulating agents (ESAs). For individuals with cancer who have iron deficiency and are receiving an ESA, we generally use IV iron due to its greater synergy with ESAs compared with oral iron [49,50]. This practice is supported by a 2012 National Comprehensive Cancer Network (NCCN) practice guideline for cancer- and chemotherapy-induced anemia, which notes that IV iron appears to have superior efficacy compared with oral iron [51]. This subject is discussed in more detail separately. (See "Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Iron monitoring and supplementation'.)

There is limited evidence to guide practice for iron supplementation in patients with cancer who are not receiving an ESA [50,52,53]. Treatment is individualized. An observational study in anemic cancer patients receiving IV iron (ferric carboxymaltose, median dose 1000 mg of elemental iron) indicated that patients with baseline hemoglobin levels up to 11.0 g/dL and serum ferritin levels up to 500 ng/mL had an increase in hemoglobin and a reduction in the need for blood transfusions [54]. Benefit was also noted for those with ferritin levels >500 ng/mL if transferrin saturation was <20 percent (mean baseline saturation, 14 percent). IV iron was well tolerated, with adverse drug reactions, mainly nausea and diarrhea, reported in 2.3 percent.

Myeloproliferative syndromes — Iron deficiency is not a problem during early stages of myeloproliferative syndromes, and iron should not be repleted in individuals undergoing therapeutic phlebotomy as a means of controlling polycythemia. An exception may be an individual with symptoms related to iron deficiency such as severe restless legs syndrome, pagophagia or pica, which may be treated with judicious use of oral (or sometimes IV) iron.

In contrast to the polycythemia that characterizes early stages of myeloproliferative syndromes, individuals can develop iron deficiency anemia later in the course of their disease. This is especially common in individuals with longstanding polycythemia vera (PV), who are likely to have been treated with multiple phlebotomies, as well as individuals with primary myelofibrosis. In addition to iron deficiency, these individuals may also have a source of bleeding that should be investigated and/or concomitant deficiencies of vitamin B12 or folate that should be addressed [55]. As noted below, transferrin saturation is a more reliable indicator of iron stores than serum ferritin. (See 'Monitoring and hemoglobin/iron targets' below.)

Heart failure — Anemia is a frequent finding in patients with heart failure (HF) and can worsen cardiac function and exacerbate symptoms. An approach to management of anemia (including iron deficiency anemia) in the setting of HF, evidence for the benefits and risks of IV iron supplementation, and society guidelines for this population are discussed in depth separately. (See "Approach to anemia in adults with heart failure", section on 'Treatment'.)

Athletes — Athletes can develop iron deficiency and anemia by a number of mechanisms including occult blood loss, hemolysis, and production of inflammatory cytokines. (See "Overtraining syndrome in athletes", section on 'Anemia' and "Approach to the adult with anemia", section on 'Athletes'.)

Therapy includes nutritional counseling and iron repletion [56,57]. A meta-analysis that evaluated iron replacement in endurance athletes with iron deficiency without anemia found therapy to be effective in improving laboratory markers of iron status and oxygen utilization [9]. (See 'Iron deficiency without anemia' above.)


Oral versus IV iron — The choice between oral and intravenous (IV) iron depends on a number of factors including the acuity of the anemia, costs and availability of different iron replacement products, as well as the ability of the patient to tolerate oral iron preparations (table 1). Most patients are treated with oral iron because it is generally effective, readily available, inexpensive, and safe. However, up to 70 percent of patients for whom oral iron is prescribed (especially ferrous sulfate) report gastrointestinal side effects [58]. (See 'Side effects (oral iron)' below.)

We generally treat patients with uncomplicated iron deficiency anemia with oral iron due to the ease of administration. However, practice in some populations is evolving [14]. There are several settings in which oral iron may be ineffective and/or poorly tolerated, and the safety of IV iron preparations is much improved over that seen historically with products such as high molecular weight iron dextran (HMW ID), which was associated with anaphylaxis and shock, including fatal events, and which has been largely removed from the market. The availability of IV iron formulations with improved toxicity profiles has lowered the threshold at which many patients would consider switching from an oral to an IV preparation.

Settings in which one route or the other may be preferable include the following:


Oral supplements are the only form of iron available to many patients, especially those in resource-poor settings.

For many patients, oral iron may be more cost effective due to the lack of need for monitored infusion.

Use of oral iron avoids the need for IV access and monitored infusion.

Use of oral iron eliminates the potential for infusion reactions and/or anaphylaxis.

Oral supplements are generally used for infants, children, and adolescents.


IV iron is appropriate for patients who are unable to tolerate gastrointestinal side effects of oral iron. Examples include older individuals, pregnant women (who already have gastrointestinal symptoms related to the pregnancy), and individuals with existing gastrointestinal disorders that may exacerbate oral iron side effects. (See 'Side effects (oral iron)' below.)

IV iron may be needed for those with severe/ongoing blood loss (eg, telangiectasias, varices).

Gastric surgery (bypass, resection) that reduces gastric acid may severely impair intestinal absorption of oral iron.

Malabsorption syndromes (celiac disease, Whipple's disease, bacterial overgrowth) may limit absorption of oral iron.

Elevated hepcidin may also reduce oral iron absorption in patients with concomitant inflammatory states [59]. This potential mechanism supports the approach of switching to IV iron in patients with iron deficiency that does not respond to oral iron supplementation. (See "Anemia of chronic disease/inflammation", section on 'Supplemental iron' and 'Uses for IV iron' below.)

Use of IV iron allows administration of nearly full-replacement doses in one or two infusions, depending on the product (table 2). In contrast, it has been estimated that the maximum amount of elemental iron that can be absorbed with an oral iron preparation is 25 mg per day [60].

A discussion of oral versus IV iron specific to patients with cancer receiving erythropoiesis-stimulating agents (ESAs) is presented separately. (See "Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Oral versus parenteral'.)

As noted below, we do not use other routes of administration such as intramuscular or transdermal iron. (See 'Routes we do not use (IM, transdermal)' below.)

Oral iron

Uses for oral iron — Oral iron provides an inexpensive and effective means of restoring iron balance in a patient with iron deficiency without complicating comorbid conditions. Uses for oral iron supplements include the following:

Treatment of iron deficiency anemia

Treatment of iron deficiency without anemia

Nutritional support to prevent deficiency

In contrast, oral iron may not be effective for individuals with ongoing blood loss, inflammatory bowel disease or gastric bypass, chronic kidney disease, or those with substantial distress from the side effects of oral iron. (See 'Oral versus IV iron' above.)

As noted above, the source of iron deficiency/site of bleeding should be addressed, and a comparison of the advantages and disadvantages of oral versus IV iron are discussed above. (See 'Initial considerations' above.)

Choice of oral preparation — Numerous oral iron formulations are available (table 3), and for the most part all are equally effective, as long as they are taken [14]. The most appropriate form is a liquid (allows for dose titration) or tablet containing ferrous salts.

Examples of available preparations (with the amount of elemental iron per dose) include:

Polysaccharide iron complex

Various over-the-counter tablets (eg, NovaFerrum 50 contains 50 mg elemental iron per tablet)

15 mg/mL oral solution (contains 15 mg elemental iron per mL)

Ferrous fumarate – 324 or 325 mg tablet (contains 106 mg elemental iron per tablet)

Ferrous gluconate

240 mg tablet (contains 27 mg elemental iron per tablet)

324 mg tablet (contains 38 mg elemental iron per tablet)

325 mg tablet (contains 36 mg elemental iron per tablet)

Ferrous sulfate

325 mg tablet (contains 65 mg elemental iron per tablet)

220 mg/5 mL oral elixir (contains 44 mg elemental iron per 5 mL)

75 mg/mL oral solution (contains 15 mg elemental iron per mL)

Additional over-the-counter preparations include heme iron polypeptide, carbonyl iron, ferric citrate, ferrous ascorbate, and ferrous succinate [14]. Among these, there is no evidence that one is more effective than another or has fewer side effects than another. All are relatively inexpensive. Other over-the-counter preparations are also widely available. Preparations such as polysaccharide-iron complex and heme iron are more expensive; these preparations are effective and may have other advantages (such as lack of metallic taste), but in a small randomized trial in young children, ferrous sulfate was slightly more effective than polysaccharide iron complex [61]. (See "Iron deficiency in infants and children <12 years: Treatment", section on 'Oral iron therapy'.)

We do not use enteric-coated or sustained-release capsules, because these preparations are poorly absorbed due to iron released too far distally in the intestinal tract; in some cases, the intact tablets are excreted in stool [62]. Iron absorption from the gut mucosal cells occurs via ferroportin, a protein localized to the duodenum and upper jejunum. We also do not use preparations such as the heme iron polypeptide ProFerrin, as these have not been evaluated clinically and their cost is greater.

Dosing and administration (oral iron) — The dose of oral iron depends on patient age, the estimated iron deficit, the rapidity with which it needs to be corrected, and side effects. For many years, the recommended daily dose for the treatment of iron deficiency in adults has been in the range of 150 to 200 mg of elemental iron daily (table 3). As an example, a 325 mg ferrous sulfate tablet contains 65 mg of elemental iron per tablet; three tablets per day will provide 195 mg of elemental iron, of which approximately 25 mg is absorbed and used in production of heme and other molecules [63]. However, the best way to administer oral iron is an area of active study, with increasing evidence suggesting that alternate-day dosing (taking the iron every other day rather than every day) may result in better iron absorption than daily dosing [63,64]. Thus, we typically advise our patients to take this dose every other day as long as they can manage the schedule appropriately; a reasonable variation on the schedule that is easier to follow is to give the dose on Monday, Wednesday, and Friday. The following evidence is relevant in this regard:

Intriguing findings from a study of the response of 54 iron-deficient women to daily oral iron suggest that giving multiple doses per day could cause a paradoxical decrease in iron absorption [65]. These women with depleted iron stores (ferritin ≤20 ng/mL) but without anemia were given various doses of oral iron that contained a traceable isotope to track absorption. Iron absorption was best when dosing was restricted to lower doses and less frequent administration (40 to 80 mg of iron no more than once a day). Higher or more frequent doses of iron raised circulating hepcidin levels and reduced subsequent fractional iron absorption.

A subsequent pair of trials assessed absorption in 60 women ages 18 to 40 years with iron deficiency (ferritin ≤25 ng/mL; most were not anemic) who were given isotope-labeled iron at different schedules [66]. In the first trial, 20 women were randomly assigned to receive same total oral daily dose of iron (120 mg of FeSO4) as a single dose or divided into two doses; this showed no difference in absorption. In the second trial, 40 women were randomly assigned to receive oral iron (60 mg of FeSO4) once daily for 14 days or once every other day for 28 days (same cumulative dose). Compared with daily dosing, every other day dosing resulted in greater iron absorption (131 versus 175 mg total). There was a trend towards decreased nausea in the every other day group that did not reach statistical significance; constipation was not assessed. It is possible that individuals assigned to alternate-day dosing were more likely to take the assigned medication; if true, this does not diminish the potential value of this approach. Additional concerns with the trial included lack of central randomization and lack of blinding; trials that address these concerns are eagerly awaited [64].

Older individuals may have greater toxicity from oral iron and may be treated with lower doses, although there is a lack of high quality evidence to guide dosing in older adults. In a randomized study in 90 hospitalized patients >80 years of age who had iron deficiency anemia, daily doses of 15, 50, or 150 mg of elemental iron for two months were equally effective in raising hemoglobin and ferritin concentrations, while adverse side effects were significantly less common at the lower iron doses [25]. When using oral iron to treat older adults with iron deficiency, we typically use 10 mL of ferrous sulfate oral elixir mixed in one-fifth of a glass of orange juice (to enhance absorption) and taken 30 minutes before breakfast, every other day. This provides 88 mg of elemental iron per dose. The dose can be reduced to 5 mL if the 10 mL dose causes irritation. An ascorbic acid (vitamin C) tablet can be substituted for the orange juice. Another option is to give a dose of oral iron once daily on Monday, Wednesday, and Friday. (See 'Older adults' above.)

The bioavailability and absorption of oral iron may be enhanced by attention to the following (table 4) [67-69]:

Food – Phosphates, phytates, and tannates in foods may bind iron and impair its absorption. (See "Regulation of iron balance", section on 'Intestinal iron absorption'.)

Iron generally should not be given with food.

Iron should especially be taken separately from calcium-containing foods and beverages (milk), calcium supplements, cereals, dietary fiber, tea, coffee, and eggs.

pH – Iron is best absorbed as the ferrous (Fe++) salt in a mildly acidic medium. Gastric acidity is helpful, and medications that reduce gastric acid (eg, antacids, histamine receptor blockers, proton pump inhibitors) may impair iron absorption.

Iron should be given two hours before, or four hours after, ingestion of antacids.

We usually coadminister a 250 mg ascorbic acid tablet or a half-glass of orange juice with iron to enhance its absorption. In a series of 12 individuals treated with iron during intake of a normal or vitamin C-supplemented diet, the absolute dose of vitamin C did not appear to have a major effect on iron absorption, and the increase in iron absorption with vitamin C was modest [70].

As noted above, enteric-coated or sustained-release capsules are less efficient for oral absorption because they release iron too far distally in the intestine (or not at all). (See 'Choice of oral preparation' above.)

The duration of treatment differs among experts and in different settings. Some stop treatment when the hemoglobin level normalizes because this allows early detection of recurrent anemia from further blood loss (eg, following therapy for a gastric lesion). Others treat for at least six months after the hemoglobin has normalized in order to completely replenish iron stores (eg, following delivery for a multigravid woman). Treatment with oral iron may take as long as six to eight weeks in order to fully ameliorate the anemia, and as long as six months to replete iron stores.

Side effects (oral iron) — Gastrointestinal side effects are extremely common with oral iron administration. These include metallic taste, nausea, flatulence, constipation, diarrhea, epigastric distress, and/or vomiting. Patients may also be bothered by itching and by black/green or tarry stools that stain clothing or cause anxiety about bleeding. As a result, compliance with oral iron administration may be low.

The magnitude and impact of these effects were demonstrated in the following:

A 2015 systematic review and meta-analysis of randomized trials included 6831 patients assigned to receive ferrous sulfate or a comparator (placebo or IV iron) [58]. The odds ratio (OR) of gastrointestinal side effects was higher with ferrous sulfate compared with placebo (OR 2.32; 95% CI 1.74-3.08) or with IV iron (OR 3.05; 95% CI 2.07-4.48). Subgroup analysis of individuals with inflammatory bowel disease or who were pregnant showed similar results. Effects were not well correlated with oral iron dose within the range of doses studied (100 to 400 mg elemental iron).

A 2013 systematic review included over 10,000 patients receiving different oral iron formulations [71]. Gastrointestinal adverse effects were seen with all oral formulations (ferrous fumarate, 43 percent; ferrous gluconate, 31 percent; ferrous sulfate, 30 percent). Other supplements such as iron protein succinate or ferrous glycine sulfate, which have enteric coating that reduces absorption, had lower frequencies of adverse effects.

As noted above, a study in older adults found that supplements containing lower amounts of elemental iron were associated with less gastrointestinal toxicity. (See 'Dosing and administration (oral iron)' above.)

Additional concerns with oral iron administration include a possible role for oral iron in altering colonic microflora and/or promoting carcinogenesis; however, no clinically significant association has been demonstrated [58,72].

Strategies to improve tolerability — Interventions to reduce the side effects of oral iron and improve tolerability include the following:

Increasing the interval (eg, to every other day) if not done already.

Making dietary modifications (eg, taking iron with food or milk), although this may reduce absorption. (See 'Dosing and administration (oral iron)' above.)

Switching to a formulation with a lower amount of elemental iron.

Switching from a tablet to a liquid, for which it is easier to titrate the dose.

Once a tolerated dose is found, the patient can sometimes increase the dose slowly as tolerated.

As noted above, for many populations, another option is switching to IV iron. Use of IV iron eliminates all of the gastrointestinal side effects of iron, which are due to direct effects of iron on the intestinal mucosa. If the patient switches to IV iron, oral iron should be discontinued. (See 'Intravenous iron' below.)

Intravenous iron

Uses for IV iron — There are a number of settings in which the use of IV iron may be preferable to oral iron [1,73,74]:

Patients who cannot (or prefer not to) tolerate the gastrointestinal side effects of oral iron.

Patients who prefer to replete iron stores in one or two visits rather than over the course of several months.

Ongoing blood loss that exceeds the capacity of oral iron to meet needs (eg, heavy uterine bleeding, mucosal telangiectasias).

Anatomic or physiologic condition that interferes with oral iron absorption.

Coexisting inflammatory state that interferes with iron homeostasis.

IV iron may be cost effective for many of these patients. However, the vast majority of iron deficient patients worldwide will not have access to IV iron due to lack of infrastructure for its administration. Additionally, some patients for whom IV iron is appropriate may wish to avoid the potential risks of adverse reactions, including infusion reactions and potential anaphylaxis, shock, and death, although this risk is exceedingly low.

For individuals who do have access to IV iron, administration may reduce the use of blood transfusion, which in turn avoids transfusion-associated risks. This was demonstrated in a 2013 systematic review and meta-analysis of trials that randomly assigned patients to IV iron versus oral iron or no iron [75]. Patients in the IV iron arms had a lower frequency of blood transfusions (risk ratio [RR] 0.74; 95% CI 0.62-0.88). The meta-analysis included trials in a number of conditions, including chronic kidney disease, inflammatory bowel disease, cancer, surgery, and pregnancy, among others (see 'Patient populations' above). Additional randomized trials published subsequently, such as a 2016 trial in 252 pregnant women, have also found that compared to oral iron, IV iron has similar efficacy in improving hemoglobin level and fewer adverse events, including markedly reduced gastrointestinal symptoms [76]. (See 'Pregnancy' above.)

Administration of IV iron should only be considered by those adequately conversant with the requirements for test dose, infusion rates, maximum allowed doses, need (if any) for premedication, and familiarity with minor infusion reactions. We avoid IV iron in patients with active infections, as many infectious agents thrive on iron, although evidence addressing this issue is lacking.

Choice of IV preparation — A number of IV iron formulations are available, including ferric carboxymaltose (FCM), ferric gluconate (FG), ferumoxytol, iron sucrose (IS), iron isomaltoside (not available in the United States), and low molecular weight iron dextran (LMW ID) (table 2).

All of these products are equally effective in treating iron deficiency [1,14]. Major differences include cost, formulary/purchasing agreements, and number of visits/time required to administer the full dose. We generally prefer LMW ID because of its low cost and ability to administer in a single dose (although the package insert specifies multiple doses; we use a single dose [1]). Other products that can be administered as a single dose include FCM, ferumoxytol, and iron isomaltoside. As discussed below, we believe the frequency of serious adverse events is comparable among products and generally do not consider this feature when choosing among products (see 'Allergic and infusion reactions' below). One exception is high molecular weight iron dextran (HMW ID), which has a greater frequency of allergic reactions [77,78]. HMW ID is no longer available in most of the world.

Cost – The relative costs of IV iron products may vary depending on local institutional purchasing agreements. In the United States, LMW ID is relatively inexpensive (typically, half the price of ferumoxytol and one-fourth the price of FCM).

Time for administration – Administration of LMW ID is done over one hour; other products may be infused more rapidly.

Number of doses required – The choice of product may also be influenced by the frequency of office visits. As examples, patients undergoing dialysis or chemotherapy may have frequent office visits during which frequent low doses of FG or IS can be administered. In contrast, patients for whom frequent visits are not otherwise necessary may prefer products that can be administered in one or two visits, such as FCM, ferumoxytol, or LMW ID.

For patients with a history of a reaction to an IV product, many experts would switch to a different IV iron product. We have successfully used different IV products in patients with serious infusion reactions to one product. This is especially true for patients who have received HMW ID, which as mentioned above was associated with more frequent adverse events and is no longer in use.

In our practice, we often use LMW ID because we treat nondialysis patients who often are seen for a single visit. We also use FCM and ferumoxytol, especially if there is insufficient time for a product that requires a longer infusion time, or if there is a history of a minor infusion reaction to LMW ID.

A comparison among IV iron products in hemodialysis patients is presented separately. (See "Treatment of iron deficiency in hemodialysis patients".)

Examples of trials comparing different IV iron products include the following:

One trial randomly assigned 605 patients with iron deficiency anemia that did not improve with oral iron therapy to receive ferumoxytol (two doses of 510 mg) or IS (five doses of 200 mg) [79]. The primary endpoint, increase in hemoglobin by ≥2 g/dL any time during five weeks of therapy, was similar between the ferumoxytol and IS groups (84 versus 81 percent). The mean change in hemoglobin was slightly higher with ferumoxytol (2.7 versus 2.4 g/dL). Adverse events were similar between groups.

Another trial randomly assigned 162 patients with chronic kidney disease and iron deficiency anemia to receive ferumoxytol (two doses of 510 mg) or IS (10 doses of 100 mg if receiving hemodialysis or five doses of 100 mg if not receiving dialysis) [80]. There was no significant difference in the mean change from baseline hemoglobin level (0.8 versus 0.7 g/dL). Adverse events were similar between groups.

Other smaller trials have shown similar findings [81,82].

Additional information regarding dosing and administration of specific products is described in the following sections. (See 'Dosing/administration of specific IV iron preparations' below.)

Dose calculation (IV iron) — The dose of iron administered depends on whether the goal is to treat anemia or to fully replace iron stores. Generally, the dose is calculated based on body weight, current hemoglobin level, and amount of elemental iron per milliliter of the iron product. A sample calculation is provided in the figure (table 5), and product information contains lookup tables based on patient weight and hemoglobin levels.

In practice, there is no evidence that total doses above 1000 mg of elemental iron are clinically useful. We often give a fixed dose of approximately 1000 mg, which is generally sufficient to treat anemia (typical red blood cell iron deficit between 500 and 1000 mg) and provide additional storage iron without causing iron overload. Whether this dose can be administered as a single (total dose) infusion or requires multiple infusions depends on the specific product.

Use of premedication — As noted below, we are concerned that a number of adverse events attributed to IV iron are in fact due to premedications, especially diphenhydramine (see 'Allergic and infusion reactions' below). Diphenhydramine may cause hypotension, somnolence, flushing, dizziness, irritability, nasal congestion, wheezing, and supraventricular tachycardia. As a result, our approach to premedication is as follows:

We do not give any premedications to patients without a history of asthma or more than one drug allergy.

For patients with asthma or more than one drug allergy, who are at slightly increased risk of an allergic or infusion reaction, we routinely premedicate with 125 mg of methylprednisolone, given intravenously prior to administration of any IV iron product [83].

For patients with a history of inflammatory arthritis, we administer methylprednisolone, 125 mg intravenously, and prescribe a short course of prednisone (1 mg/kg per day orally for four days) [83].

We (and others) do not use antihistamines to prevent (or treat) infusion reactions [73,84,85].

We administer every IV iron product slowly at first and observe patients for infusion reactions. Specific infusion durations are described in the sections on individual products.

Treatment of infusion reactions is discussed below. (See 'Allergic and infusion reactions' below.)

Dosing/administration of specific IV iron preparations

LMW iron dextran — LMW ID (INFeD, CosmoFer) is the least expensive of the IV iron formulations that can be administered in a single, large dose (total dose infusion) (table 2).

LMW ID can be given as multiple doses of 2 mL (equivalent to 100 mg elemental iron, based on a concentration of 50 mg elemental iron per mL). LMW ID can also be given as a single, total dose infusion; this practice has been shown to be safe and effective in the settings of heavy uterine bleeding, pregnancy, postpartum, inflammatory bowel disease, gastric bypass, hereditary hemorrhagic telangiectasia, chronic kidney disease, and restless legs syndrome [12,86,87]. We often give a total dose infusion of 1000 mg in 250 mL of normal saline over one hour. Although this is not a US Food and Drug Administration-approved dosing, we have not observed any serious adverse events with this approach in over 5000 administrations [12].

A test dose is required prior to the first dose of LMW ID (0.5 mL [25 mg]). This may be given gradually over at least 30 seconds; we prefer to administer the test dose over five minutes while observing the patient. If no symptoms occur during the first 5 to 10 minutes, it is extremely unlikely that an infusion reaction will occur. After the test dose, we administer the remainder of a 1000 mg dose over the balance of one hour.

In contrast to LMW ID, we do not use HMW ID, as risks of severe reactions are much greater with the HMW product [88,89]. The HMW product is largely unavailable.

Ferric gluconate — Ferric gluconate (FG; Ferrlecit), also called ferric gluconate complex, can be given over multiple infusions. A typical dose is 10 to 15 mL (equivalent to 125 to 187.5 mg elemental iron, based on a concentration of 12.5 mg elemental iron per mL) (table 2). A test dose is recommended if the patient has a history of drug allergies. While a test dose is not required for patients without a history of drug allergies, we administer all iron formulations slowly at first and observe patients for infusion reactions.

Each dose of 10 to 15 mL can be administered as a two-minute bolus (eg, in patients undergoing hemodialysis) or diluted in normal saline and infused over 20 to 30 minutes. One group has reported administration of 125 mg diluted in 100 mL of normal saline and infused over 30 to 60 minutes [90]. Although rarely done, 250 mg infusions over one hour have been reported to be well tolerated [91]. Larger single doses should not be attempted. This product cannot be given intramuscularly.

Iron sucrose — Iron sucrose (IS; Venofer) also called iron saccharate, is given over multiple infusions, with a maximum individual dose of 10 to 15 mL (equivalent to 200 to 300 mg elemental iron, based on a concentration of 20 mg elemental iron per mL). A test dose (1.25 mL [25 mg] by slow IV push) is recommended if the patient has a history of drug allergies; otherwise, a test dose is not required.

Doses of 10 mL (200 mg elemental iron) are routinely given over 2 to 15 minutes in dialysis centers; a total of five doses is common [92]. For patients with cancer receiving ESAs, 10 mL may be infused over 60 minutes every two to three weeks. Larger doses (ie, doses above 300 mg) are not recommended [93]. This product cannot be given intramuscularly.

IS has been shown to be safe and effective in settings of dialysis, nondialysis chronic kidney disease, inflammatory bowel disease, chemotherapy-induced anemia, the peripartum period, gastric bypass, heavy uterine bleeding, and a host of other conditions associated with iron deficiency.

Ferumoxytol — Ferumoxytol (Feraheme) is composed of superparamagnetic iron oxide nanoparticles coated with a LMW semisynthetic carbohydrate. It can be given in doses of 17 mL (equivalent to 510 mg of elemental iron, based on a concentration of 30 mg of elemental iron per mL) (table 2).

Typically, patients are treated with two doses of ferumoxytol (510 mg elemental iron per dose) administered three to eight days apart. The infusion rate of ferumoxytol was revised from initial product labeling (1 mL per second of the undiluted solution), to a 15-minute infusion requiring dilution in 50 to 250 mL of normal saline or glucose solution. This change was based on postmarketing surveillance reports that documented a large number of infusion reactions with the 17-second infusion [80,94,95]. In one of our practices (MA), we initially used an infusion rate of 17 to 30 seconds; this resulted in 3 of 90 patients (3.3 percent) developing hypotension requiring fluid administration. Subsequently, we have given over 1900 doses at an infusion rate of approximately three minutes (90 to 180 seconds) without any adverse events [14]. We have also treated 60 patients with the entire supplement (two 510 mg doses, for a total of 1020 mg) in a single 15-minute infusion, without any serious adverse events [96]. In the absence of a clinical trial, it is prudent to follow approved labeling and use the 15-minute infusion [97-99]. There are no published data on the safety and efficacy of ferumoxytol in pregnancy.

In a 2018 trial that randomly assigned 1997 iron-deficient adults to receive ferumoxytol (two infusions of 510 mg for a total of 1020 mg) versus ferric carboxymaltose (two infusions of 750 mg for a total of 1500 mg), both groups had comparable increases in hemoglobin (approximate increase, 1.5 g/dL) [100]. There were no major between-group differences in the rates of moderate-to-severe hypersensitivity reactions, all of which were rare (incidence, <1 percent). There were no episodes of anaphylaxis. There were six deaths, none of which were considered to be treatment-related. Compared with ferumoxytol, hypophosphatemia was more common with ferric carboxymaltose (0.4 versus 38.7 percent), but no clinical sequelae related to hypophosphatemia were seen in either group.

Ferumoxytol can cause a brighter signal on magnetic resonance imaging (MRI) scans, which is important to be aware of but does not negatively affect interpretation of the scan. If an MRI is planned within three months of administration, the radiologist should be notified that the patient has received ferumoxytol.

Ferric carboxymaltose — Ferric carboxymaltose (FCM; Ferinject, Injectafer) is a colloidal iron hydroxide complex with tighter binding of elemental iron to the carbohydrate polymer than some other IV iron preparations. FCM can be given as a dose of up to 20 mL (equivalent to 1000 mg of elemental iron, based on a concentration of 50 mg of elemental iron per mL) (table 2); product labeling specifies a maximum dose of 20 mg per kg of body weight.

Doses of FCM may be given over a 15-minute infusion. We often administer a dose of 750 mg (the vial size available in the United States). As with all formulations, we start slowly, observe for signs of allergy or infusion reaction, and if not seen, administer the balance over 15 minutes. If appropriate, a second dose of 750 mg can be given on a different day. A number of trials have shown efficacy and safety of this agent in iron-deficient patients in a number of different settings including heavy uterine bleeding, postpartum women, nondialysis-dependent chronic renal failure, inflammatory bowel disease, heart failure, chemotherapy-associated anemia without concomitant use of an ESA, and nonresponse to oral iron [54,59,101-107]. Several series have reported use of FCM during pregnancy without serious adverse events [108-110].

Initial experience with FCM raised concerns about hypophosphatemia observed following administration. Subsequently, only rare reports of clinical sequelae related to hypophosphatemia have been reported [111-114]. Serum phosphate levels may need to be monitored in selected populations such as those with borderline phosphate levels at baseline [115].

Iron isomaltoside — Iron isomaltoside (Monofer) is available only in Europe. It has a matrix structure that results in tight iron binding and slow release of labile free iron, allowing administration in a single infusion, at a dose of 20 mg/kg, over 15 minutes. A test dose is not required. The elemental iron concentration is 100 mg/mL.

In a 2017 trial that randomly assigned 511 patients to receive a single infusion of iron isomaltoside (500 or 1000 mg, depending on body weight and hemoglobin level) or multiple infusions of iron sucrose (given as 200 mg infusions, for a total dose based on body weight and hemoglobin), a greater number of patients in the iron isomaltoside group had an increase in hemoglobin of ≥2 g/dL (69 versus 52 percent; p<0.0001) [116]. Rates of serious adverse events did not differ (0.6 percent in both groups).

The safety and efficacy of iron isomaltoside have also been reported in selected patient populations:

Chronic kidney disease [117,118]

Inflammatory bowel disease [119]

Cardiac surgery [44]

Chemotherapy-induced anemia [120]

Postpartum hemorrhage [121]

Iron deficiency of mixed etiology [122]

Two prospective studies are underway in the United States for the treatment of iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease [123,124].

Allergic and infusion reactions

Risks/prevention — IV iron has the potential to cause allergic reactions, including potentially life-threatening anaphylaxis. However, we believe these serious allergic reactions are exceedingly rare and vastly overestimated [1].

In contrast to serious allergic reactions, IV iron may be associated with nonallergic infusion reactions including self-limiting urticaria, palpitations, dizziness, and neck and back spasm; generally, these occur in <1 percent of individuals and do not progress to more serious reactions [90]. Similar to allergic reactions, higher rates of nonallergic reactions were seen with high molecular weight (HMW) iron dextran, which is no longer used. Trials involving IV iron product comparisons generally have shown similar rates of these infusion reactions between products. (See 'Choice of IV preparation' above.)

In addition, patients with a history of inflammatory arthritis (eg, rheumatoid arthritis) commonly experience a flare of their arthritis during IV iron infusion, which is usually well-controlled with glucocorticoid premedication and/or a brief course of glucocorticoids (three to four days) following the infusion (see 'Treatment' below). The cause of these exacerbations of inflammatory arthritis is incompletely understood but may involve effects of oxidant stress [125].

Many clinicians are reluctant to use IV iron due to experience in the era before modern products were available, when allergic reactions (including severe reactions) were more common, as well as misunderstanding of the distinction between rate-related infusion reactions and true allergic reactions, which may have been challenging to distinguish when first encountered [84,126]. Further, misinterpretation of a rate-related infusion reaction as an allergic reaction may lead to interventions that convert a minor side effect into a serious adverse event, further reinforcing the mistaken impression that the product is dangerous [127]. In a typical scenario, myalgias, including chest and back discomfort, may be mistakenly ascribed to anaphylaxis, prompting administration of antihistamines and/or epinephrine, which in turn causes tachycardia and/or hypotension, converting the minor reaction to a more serious event.

Further support for the impression that these infusion reactions are not allergic comes from our experience, in which we have measured serum tryptase levels at the time of the reaction, and have found these levels not to be elevated [14,96].

Our approach to reducing the risks of allergic and infusion reactions is as follows [1]:

We avoid administration of a product to which a patient has had a serious, well-documented hypersensitivity reaction. However, as noted above, some patients may be successfully switched to a different product. (See 'Choice of IV preparation' above.)

We warn patients (and infusion personnel) in advance of the infusion that they may experience self-limiting fever, arthralgias, and myalgias, either during the infusion or within 24 hours, and that this does not represent an allergic reaction or cause for panic [83].

We avoid premedications for patients without asthma or multiple drug allergies. For individuals with asthma or multiple drug allergies, we generally limit premedication to a glucocorticoid alone (methylprednisolone, 125 mg intravenously). (See 'Use of premedication' above.)

For patients with a history of inflammatory arthritis, we administer methylprednisolone, 125 mg intravenously, and prescribe a short course of prednisone (1 mg/kg per day orally for four days) [83].

We generally limit interventions to minor reactions to temporarily stopping the infusion until the symptoms abate. (See 'Treatment' below.)

There are no immediately available clinical parameters that can unequivocally distinguish between an infusion reaction (nonallergic, often rate-related) and an allergic/anaphylactic reaction, and the vast majority of publications have been unable to definitively distinguish between these reactions. In most cases, treatment may be the same, involving stopping the drug with close observation for minor reactions and aggressive interventions for life-threatening reactions (see 'Treatment' below). While it is prudent to take all reactions seriously, we believe most reactions are due to infusional symptoms (rather than a true allergy), and should be managed as such.

When the above tenets are followed (and the use of HMW ID is avoided), serious adverse events with IV iron are extremely rare, with an estimated frequency of less than 1:200,000. Information about the frequency of infusional and allergic reactions associated with IV iron has been evaluated in the following studies:

A 2015 review retrospectively compared rates of anaphylaxis among 688,183 individuals who received an IV iron product while enrolled in the United States Medicare program (a large section of the United States population, typically ≥65 years of age) [128]. Overall risks of anaphylaxis were low (range, 24 to 68 cases per 100,000 individuals [0.024 to 0.068 percent]), and some deaths were recorded. However, we believe this may overestimate the frequency of serious reactions because the criteria for anaphylaxis were based on medical coding data that did not allow the investigators to determine whether administration of an antihistamine and wheezing preceded or followed iron administration [129]. This study found rates of anaphylaxis to be higher with ID than other products; however, the rates with ID may also be an overestimate as they included the HMW ID that is known to have a higher risk of adverse reactions and is no longer used. Further, these results may not be directly applicable to a younger population.

A 2015 systematic review and meta-analysis that included 103 randomized trials of IV iron versus another comparator (eg, oral iron, placebo) found no increased risk of serious adverse events attributable to IV iron (relative risk [RR] 1.04; 95% CI 0.93-1.17) [130]. There were no deaths or anaphylactic reactions in over 10,000 patients who received IV iron. However, severe infusion reactions were more common with IV iron than comparators (RR 2.47; 95% CI 1.43-4.28). As expected, gastrointestinal side effects were lower with IV iron.

Case reports have described life-threatening adverse events for all of the available IV iron preparations [89,131,132]. True allergic reactions to IV iron products (with documented increases in mast cell tryptase) also have been reported [133,134]. However, we believe these are exceedingly rare and comparable to the incidence of severe allergic reactions to many commonly used medications. As noted above, we have measured tryptase levels in patients who have had infusion reactions with LMW ID and ferumoxytol, and we have found these levels not to be elevated [14].

We consider the US Food and Drug Administration's Adverse Event Reporting System (AERS) a valuable resource for reporting suspected allergic/anaphylactic reactions, but conclusions about absolute risks and/or relative risks among products should not be inferred from the AERS database or other voluntarily submitted reports [89,131,135,136].

Treatment — All clinicians administering IV iron should have adequate personnel, training, and equipment to manage extremely rare but potentially life-threatening adverse events, including medications to treat anaphylaxis, resuscitation equipment, and provisions for intensive care management. For the overwhelming majority of patients receiving IV iron, these resources will never be used.

Our approach to managing adverse reactions, should they occur, includes the following [1,78,84,137]:

Transient fever, arthralgias, myalgias, or flushing are generally seen in approximately 0.5 to 1 percent of infusions. For patients who develop these symptoms without associated hypotension, tachypnea, tachycardia, wheezing, stridor, or periorbital edema, we temporarily hold the infusion and observe the patient.

We do not administer antihistamines or other medications, as these may worsen rather than improve symptoms.

If symptoms resolve, we resume and complete the infusion (most common outcome).

If symptoms worsen, we treat as a more serious reaction.

If symptoms persist unchanged, we may administer a dose of intravenous methylprednisolone, wait 30 minutes, and reinitiate the iron infusion; a short course of oral methylprednisolone also may be administered.

Patients are informed that should they develop these symptoms after leaving the infusion facility, they may derive benefit with nonsteroidal anti-inflammatory drugs (NSAIDs), as long as these are clinically appropriate.

For patients with more serious or true anaphylactic reactions, we treat according to standard protocols. (See "Anaphylaxis: Emergency treatment".)

For patients with inflammatory arthritis who experience a disease flare, we administer methylprednisolone, 125 mg intravenously, and prescribe a short course of prednisone (1 mg/kg per day orally for four days).

These guidelines are summarized in the table (table 6).

Risk of infection — Bacteria and other infectious agents require iron as a growth factor, and patients with hereditary hemochromatosis and iron overload are known to be at increased risk for certain serious bacterial infections [138]. These observations have suggested that the use of therapeutic doses of iron might be associated with an increased risk of infection.

We believe the risk of infection with IV iron administration is negligible. This is supported by a 2015 meta-analysis of trials comparing outcomes with IV iron versus controls including oral iron, intramuscular iron, placebo, or no iron (RR 1.17; 95% CI 0.83-1.65) [130]. A 2013 meta-analysis of this subject found a slightly increased risk of infection with IV iron compared with oral iron (RR 1.33; 95% CI 1.10-1.64), but it was acknowledged that information on the risk of infection was available in only 24 of the 72 studies, and missing data could have created bias [75]. Additionally, there was no dose-response association between iron and infectious risk, and rates of mortality and other serious adverse events were not increased with IV iron treatment. Additional trials and observational studies in specific patient populations also have not demonstrated increased infectious risks [47,104,107,139-141].

As noted above, we delay IV iron administration in patients with active infection until the infection is resolved. (See 'Uses for IV iron' above.)

Routes we do not use (IM, transdermal) — In contrast to oral and IV iron, we do not use other routes of administration.

Intramuscular – Intramuscular (IM) iron is available and will raise the iron level, but this route of administration is painful, stains the buttocks, and has variable absorption [137]. Case reports have also described development of sarcoma following IM iron administration [142,143].

Transdermal – Transdermal iron delivery systems are being studied in animal models [144]. However, there is no clinical evidence in humans that the transdermal route is effective or safe.


Typical response — An effective regimen for the treatment of uncomplicated iron deficiency with oral iron preparations should lead to the following responses:

If pagophagia (pica for ice) is present, it often disappears almost as soon as oral or intravenous (IV) iron therapy is begun, well before there are any observable hematologic changes such as reticulocyte response. (See "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Pica and ice craving'.)

The patient will note an improved feeling of well-being within the first few days of treatment.

In patients with moderate to severe anemia, a modest reticulocytosis will be seen, peaking in approximately 7 to 10 days. Patients with mild anemia may have little or no reticulocytosis.

The hemoglobin concentration will rise slowly, usually beginning after approximately one to two weeks of treatment, and will rise approximately 2 g/dL over the ensuing three weeks. The hemoglobin deficit should be halved by approximately one month, and the hemoglobin level should return to normal by six to eight weeks.

Typically, papillation of the tongue is decreased in patients with iron deficiency and can be used as a gauge of duration of symptoms. Classically, loss of papillae begins at the tip and lateral borders, and moves posteriorly and centrally. Following iron repletion, a rapid correction (weeks to months) is observed.

Monitoring and hemoglobin/iron targets — Monitoring of patients receiving iron replacement depends on the severity of anemia.

For patients receiving oral iron, we often re-evaluate the patient two weeks after starting. We check the hemoglobin and reticulocyte count and review tolerability of the oral iron. For IV iron, we generally see patients four to eight weeks after the iron has been administered. We do not obtain repeat iron parameters for at least four weeks, because IV iron interferes with most assays of iron status [145]. Patients with ongoing blood loss (eg, hereditary hemorrhagic telangiectasia) may require frequent visits to establish an effective iron dose and teach the patient how to monitor ongoing blood loss.

Iron is generally given until levels of ferritin and transferrin saturation normalize. When ferritin and transferrin saturation are discordant, we place greater emphasis on the transferrin saturation. Ferritin is an acute phase reactant and may be chronically elevated in individuals with concomitant inflammatory processes even when iron stores are low. (See "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Diagnostic evaluation'.)

Total body iron stores in adults are generally in the range of 5 mg/kg in women and 10 mg/kg in men. Thus, correction of anemia plus repletion of iron stores may require up to a gram or more of elemental iron. (See "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Normal body iron content'.)

Approaches to lack of response — On occasion, a patient's hemoglobin level and iron stores may not normalize with iron supplementation. There are a number of potential causes for this situation (table 7):

Patient not taking oral iron (eg, due to side effects) (see 'Side effects (oral iron)' above)

Reduced absorption of oral iron (see 'Dosing and administration (oral iron)' above)

Blood loss exceeds iron intake

Incorrect initial diagnosis

More than one diagnosis (especially relevant in older adults)

Inflammatory state with block in intestinal iron regulation (figure 1)

Therapy was effective but bleeding recurred

For those who are taking the iron supplement and do not have an obvious explanation for lack of an increase in hemoglobin level and iron stores, it may be prudent to screen for celiac disease and/or Helicobacter pylori infection, both of which have been implicated in reduced oral iron absorption. Celiac disease in particular has additional management implications if present. (See "Diagnosis of celiac disease in children" and "Diagnosis of celiac disease in adults" and "Indications and diagnostic tests for Helicobacter pylori infection".)

Some individuals whose anemia does not respond to oral iron due to an inflammatory block may benefit from IV iron. This has been demonstrated in various trials in various populations. As examples:

A series of 812 patients with iron deficiency who were unable to tolerate oral iron or whose hemoglobin did not increase with oral iron were randomly assigned to receive IV iron (ferumoxytol, two 510 mg doses one week apart) versus placebo [95]. Compared with placebo, patients who received IV iron were more likely to have an increase in hemoglobin of ≥2 g/dL at week 5 (6 versus 81 percent). Other endpoints such as hemoglobin ≥12 g/dL and functional fatigue score also favored the IV iron arm.

A series of 240 iron-deficient patients who participated in a trial that stratified them according to initial response to oral iron at two weeks [59]. Compared with responders, nonresponders had higher hepcidin levels (11 versus 38 ng/mL). In a subset of 45 nonresponders randomly assigned to receive additional oral iron or IV iron (ferric carboxymaltose [FCM]), FCM was more effective at increasing hemoglobin levels (hemoglobin increase of ≥1 g/dL in 65 versus 21 percent).

Other individuals may have additional diagnoses, either initially misdiagnosed as iron deficiency, concomitant with iron deficiency, or rarely, developing during treatment of iron deficiency. Examples include nutrient deficiencies (vitamin B12, folate), bone marrow abnormalities (myelodysplastic syndrome), inherited anemias (thalassemia, enzyme defects), hypothyroidism, other genetic conditions that affect iron balance such as iron-resistant iron deficiency anemia (IRIDA), and disorders associated with chronic inflammation. Investigation for these (indications and appropriate testing) is discussed in separate topic reviews. (See "Approach to the child with anemia" and "Approach to the adult with anemia" and "Anemia in the older adult" and "Anemia of chronic disease/inflammation" and "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Inherited disorders/IRIDA'.)

Celiac disease, autoimmune gastritis, and Helicobacter pylori infection have been reported to interfere with absorption of oral iron. It has been reported that over half of patients with unexplained iron deficiency anemia are infected with H. pylori, and patients with H. pylori infection have a pooled odds ratio of iron deficiency of 2.8 compared with uninfected individuals [146]. In a series of 150 patients with unexplained iron deficiency anemia, there were eight newly diagnosed cases of adult celiac disease (5 percent); 40 cases (27 percent) of autoimmune gastritis, 22 of which were associated with previously undetected vitamin B12 deficiency (27 and 15 percent, respectively); and 77 cases of H. pylori infection, 29 of which had H. pylori as the sole abnormality detected (55 and 19 percent, respectively) [147]. Of 26 evaluable H. pylori-positive patients who had successful H. pylori eradication followed by administration of oral iron, 19 (73 percent) had a response, with mean increase in hemoglobin from 9.4 mg/dL to 13.5 mg/dL.

As noted above, some of these diagnoses, such as celiac disease, may be especially important to evaluate. The specific sequence and extent of testing for causes of lack of response is guided by the patient’s family history, medical history, and physical examination. This evaluation (and appropriate additional treatments based on the results) is discussed separately. (See "Approach to the adult with anemia" and "Anemia in the older adult".)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Anemia in adults".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topics (see "Patient education: Anemia caused by low iron (The Basics)")

Beyond the Basics topics (see "Patient education: Anemia caused by low iron in adults (Beyond the Basics)")


Regardless of the presence of symptoms, all patients with iron deficiency anemia and most patients with iron deficiency without anemia should be treated. The cause of iron deficiency also must be identified and addressed, especially in adults with new onset iron deficiency. (See 'Initial considerations' above.)

Patients with severe, severely symptomatic (eg, with symptoms of myocardial ischemia), or life-threatening anemia should be treated with red blood cell (RBC) transfusion. (See 'Severe/life-threatening anemia' above.)

Some conditions may affect iron dosing and/or the route of administration (oral versus intravenous [IV]) (table 1). We generally treat patients who have uncomplicated iron deficiency anemia with oral iron due to the ease of administration. However, the availability of IV iron formulations with improved toxicity profiles has lowered the threshold at which many patients would prefer an IV preparation. We often use IV iron when treating pregnant women and individuals with inflammatory bowel disease, gastric surgery, or chronic kidney disease. (See 'Oral versus IV iron' above and 'Pregnancy' above and 'Older adults' above and 'Inflammatory bowel disease' above and 'Gastrointestinal/bariatric surgery' above and 'Other surgeries/perioperative' above and 'Chronic kidney disease' above and 'Heart failure' above and 'Helicobacter and gastritis' above.)

For the most part, all oral iron preparations are equally effective (table 3). The dose of oral iron depends on patient age, the estimated iron deficit, the rapidity with which it needs to be corrected, and side effects, which include metallic taste, and a number of gastrointestinal effects that generally correlate with dose. For individuals treated with oral iron, we suggest that the dose be taken every other day rather than every day (Grade 2C). This is based on evidence in individuals with iron deficiency that demonstrates improved absorption and reduced gastrointestinal side effects. Other strategies to improve tolerability are listed above. (See 'Oral iron' above.)

There are a number of settings in which IV may be preferable to oral administration, including ongoing blood loss, physiologic or anatomic abnormality that interferes with oral absorption or iron homeostasis, and intolerable gastrointestinal side effects of oral iron. A number of IV iron formulations are available (table 2); their dosing and administration are described above. (See 'Choice of IV preparation' above and 'Dosing/administration of specific IV iron preparations' above.)

Many clinicians are reluctant to use IV iron due to concerns about anaphylaxis. We believe true allergic reactions are exceedingly rare and vastly overestimated, largely due to experience with older products such as high molecular weight iron dextran (HMW ID), which is no longer used, and the practice of aggressively treating nonallergic infusion reactions with diphenhydramine and other therapies that convert the reaction to a more serious event. We do not use routine premedication prior to IV iron and we avoid diphenhydramine. For individuals with asthma, inflammatory rheumatic conditions, or multiple drug allergies, we generally limit premedication to a glucocorticoid alone. (See 'Allergic and infusion reactions' above.)

Effective treatment of iron deficiency results in resolution of symptoms, a modest reticulocytosis (peaking in 7 to 10 days), and normalization of the hemoglobin level in six to eight weeks. Causes for a lack of response include nonadherence to oral iron, ongoing blood loss, and incorrect initial diagnosis or the presence of additional diagnoses. Some of these additional diagnoses, such as celiac disease, may be especially important to evaluate. (See 'Response to iron supplementation' above.)

Use of UpToDate is subject to the Subscription and License Agreement.


  1. Auerbach M, Deloughery T. Single-dose intravenous iron for iron deficiency: a new paradigm. Hematology Am Soc Hematol Educ Program 2016; 2016:57.
  2. Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118:3222.
  3. Sharma R, Stanek JR, Koch TL, et al. Intravenous iron therapy in non-anemic iron-deficient menstruating adolescent females with fatigue. Am J Hematol 2016; 91:973.
  4. Patterson AJ, Brown WJ, Roberts DC. Dietary and supplement treatment of iron deficiency results in improvements in general health and fatigue in Australian women of childbearing age. J Am Coll Nutr 2001; 20:337.
  5. Verdon F, Burnand B, Stubi CL, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 2003; 326:1124.
  6. Vaucher P, Druais PL, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ 2012; 184:1247.
  7. Rowland TW, Deisroth MB, Green GM, Kelleher JF. The effect of iron therapy on the exercise capacity of nonanemic iron-deficient adolescent runners. Am J Dis Child 1988; 142:165.
  8. Pittori C, Buser A, Gasser UE, et al. A pilot iron substitution programme in female blood donors with iron deficiency without anaemia. Vox Sang 2011; 100:303.
  9. Burden RJ, Morton K, Richards T, et al. Is iron treatment beneficial in, iron-deficient but non-anaemic (IDNA) endurance athletes? A systematic review and meta-analysis. Br J Sports Med 2015; 49:1389.
  10. Achebe MM, Gafter-Gvili A. How I treat anemia in pregnancy: iron, cobalamin, and folate. Blood 2017; 129:940.
  11. Drukker L, Hants Y, Farkash R, et al. Iron deficiency anemia at admission for labor and delivery is associated with an increased risk for Cesarean section and adverse maternal and neonatal outcomes. Transfusion 2015; 55:2799.
  12. Auerbach M, Pappadakis JA, Bahrain H, et al. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 2011; 86:860.
  13. Wong L, Smith S, Gilstrop M, et al. Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy. Am J Hematol 2016; 91:590.
  14. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol 2016; 91:31.
  15. Auerbach M, James SE, Nicoletti M, et al. Results of the First American Prospective Study of Intravenous Iron in Oral Iron-Intolerant Iron-Deficient Gravidas. Am J Med 2017; 130:1402.
  16. Reveiz L, Gyte GM, Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database Syst Rev 2011; :CD003094.
  17. Congdon EL, Westerlund A, Algarin CR, et al. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years. J Pediatr 2012; 160:1027.
  18. Bencaiova G, von Mandach U, Zimmermann R. Iron prophylaxis in pregnancy: intravenous route versus oral route. Eur J Obstet Gynecol Reprod Biol 2009; 144:135.
  19. Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG 2006; 113:1248.
  20. Al RA, Unlubilgin E, Kandemir O, et al. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 2005; 106:1335.
  21. Bayoumeu F, Subiran-Buisset C, Baka NE, et al. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol 2002; 186:518.
  22. Khalafallah A, Dennis A, Bates J, et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med 2010; 268:286.
  23. Khalafallah AA, Dennis AE, Ogden K, et al. Three-year follow-up of a randomised clinical trial of intravenous versus oral iron for anaemia in pregnancy. BMJ Open 2012; 2.
  24. Henry DH, Dahl NV, Auerbach MA. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 2012; 87:308.
  25. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med 2005; 118:1142.
  26. Gomollón F, Gisbert JP. Intravenous iron in inflammatory bowel diseases. Curr Opin Gastroenterol 2013; 29:201.
  27. Jimenez K, Gasche C, Auerbach M. On both sides of the ocean. Blood Transfus 2016; 14:197.
  28. de Silva AD, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflamm Bowel Dis 2003; 9:316.
  29. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40:1058.
  30. Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut 2017; 66:863.
  31. Gasché C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997; 126:782.
  32. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996; 334:619.
  33. García-López S, Bocos JM, Gisbert JP, et al. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfus 2016; 14:199.
  34. Schröder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100:2503.
  35. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13:1545.
  36. Reinisch W, Chowers Y, Danese S, et al. The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther 2013; 38:1109.
  37. Gasche C, Evstatiev R, Haas T, et al. [Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party]. Z Gastroenterol 2011; 49:627.
  38. Stein J, Bager P, Befrits R, et al. Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. Eur J Gastroenterol Hepatol 2013; 25:1456.
  39. Bodemar G, Kechagias S, Almer S, Danielson BG. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 2004; 39:454.
  40. Mamula P, Piccoli DA, Peck SN, et al. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 34:286.
  41. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009; 44:838.
  42. Kim YW, Bae JM, Park YK, et al. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial. JAMA 2017; 317:2097.
  43. Khalafallah AA, Yan C, Al-Badri R, et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Lancet Haematol 2016; 3:e415.
  44. Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang 2015; 109:257.
  45. Froessler B, Palm P, Weber I, et al. The Important Role for Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery: A Randomized Controlled Trial. Ann Surg 2016; 264:41.
  46. Serrano-Trenas JA, Ugalde PF, Cabello LM, et al. Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial. Transfusion 2011; 51:97.
  47. Muñoz M, Gómez-Ramírez S, Cuenca J, et al. Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. Transfusion 2014; 54:289.
  48. Hershko C, Ronson A. Iron deficiency, Helicobacter infection and gastritis. Acta Haematol 2009; 122:97.
  49. Auerbach M, Liang AS, Glaspy J. Intravenous iron in chemotherapy and cancer-related anemia. Community Oncol 2012; 9:289.
  50. Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol 2013; 52:18.
  51. Rodgers GM 3rd, Becker PS, Blinder M, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012; 10:628.
  52. Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007; 105:199.
  53. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010; 116:522.
  54. Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013; 24:475.
  55. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100:4272.
  56. Clénin G, Cordes M, Huber A, et al. Iron deficiency in sports - definition, influence on performance and therapy. Swiss Med Wkly 2015; 145:w14196.
  57. Alaunyte I, Stojceska V, Plunkett A. Iron and the female athlete: a review of dietary treatment methods for improving iron status and exercise performance. J Int Soc Sports Nutr 2015; 12:38.
  58. Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One 2015; 10:e0117383.
  59. Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88:97.
  60. Werner E, Kaltwasser JP, Ihm P. [Oral iron treatment: intestinal absorption and the influence of a meal (author's transl)]. Dtsch Med Wochenschr 1977; 102:1061.
  61. Powers JM, Buchanan GR, Adix L, et al. Effect of Low-Dose Ferrous Sulfate vs Iron Polysaccharide Complex on Hemoglobin Concentration in Young Children With Nutritional Iron-Deficiency Anemia: A Randomized Clinical Trial. JAMA 2017; 317:2297.
  62. Boggs DR. Fate of a ferrous sulfate prescription. Am J Med 1987; 82:124.
  63. Schrier SL. So you know how to treat iron deficiency anemia. Blood 2015; 126:1971.
  64. Auerbach M, Schrier S. Treatment of iron deficiency is getting trendy. Lancet Haematol 2017; 4:e500.
  65. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015; 126:1981.
  66. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017; 4:e524.
  67. Crosby WH. The rationale for treating iron deficiency anemia. Arch Intern Med 1984; 144:471.
  68. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med 2008; 121:943.
  69. DeLoughery TG. Microcytic anemia. N Engl J Med 2014; 371:1324.
  70. Cook JD, Reddy MB. Effect of ascorbic acid intake on nonheme-iron absorption from a complete diet. Am J Clin Nutr 2001; 73:93.
  71. Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin 2013; 29:291.
  72. Lund EK, Wharf SG, Fairweather-Tait SJ, Johnson IT. Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr 1999; 69:250.
  73. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372:1832.
  74. Röhrig G, Steinmetz T, Stein J, et al. [Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies]. MMW Fortschr Med 2014; 156 Suppl 2:48.
  75. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 2013; 347:f4822.
  76. Breymann C, Milman N, Mezzacasa A, et al. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med 2016.
  77. Rodgers GM, Auerbach M, Cella D, et al. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol 2008; 19:833.
  78. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010; 2010:338.
  79. Hetzel D, Strauss W, Bernard K, et al. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol 2014; 89:646.
  80. Macdougall IC, Strauss WE, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014; 9:705.
  81. Sav T, Tokgoz B, Sipahioglu MH, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007; 29:423.
  82. Kosch M, Bahner U, Bettger H, et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001; 16:1239.
  83. Auerbach M, Chaudhry M, Goldman H, Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med 1998; 131:257.
  84. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014; 99:1671.
  85. Bircher AJ, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am 2014; 34:707.
  86. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998; 31:81.
  87. Ondo WG. Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Med 2010; 11:494.
  88. Auerbach M, Rodgers GM. Intravenous iron. N Engl J Med 2007; 357:93.
  89. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:378.
  90. Miller HJ, Hu J, Valentine JK, Gable PS. Efficacy and tolerability of intravenous ferric gluconate in the treatment of iron deficiency anemia in patients without kidney disease. Arch Intern Med 2007; 167:1327.
  91. Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration. Am J Kidney Dis 2003; 41:651.
  92. Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 2005; 46:283.
  93. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38:988.
  94. Rosner MH, Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert Rev Hematol 2011; 4:399.
  95. Vadhan-Raj S, Strauss W, Ford D, et al. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol 2014; 89:7.
  96. Auerbach M, Strauss W, Auerbach S, et al. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Am J Hematol 2013; 88:944.
  97. FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol) [3-30-15] (Accessed on April 02, 2015).
  98. Ferumoxytol injection. US FDA prescribing information (revised March, 2015) (Accessed on April 02, 2015).
  99. FERAHEME (ferumoxytol) - Important Changes to the Delivery and New Restrictions on the Use Due to Information on Serious Allergic Reactions - For Health Professionals [November 21, 2014] (Accessed on April 02, 2015).
  100. Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. Am J Hematol 2018.
  101. Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110:267.
  102. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008; 101:67.
  103. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103:1182.
  104. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:2436.
  105. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49:2719.
  106. Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2014; 54:306.
  107. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29:2075.
  108. Christoph P, Schuller C, Studer H, et al. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med 2012; 40:469.
  109. Schneider J, Krafft A, Manconi M, et al. Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome. Sleep Med 2015; 16:1342.
  110. Froessler B, Collingwood J, Hodyl NA, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnancy Childbirth 2014; 14:115.
  111. Smyth B, Ong S. Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction. Intern Med J 2016; 46:360.
  112. Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. Neth J Med 2014; 72:49.
  113. Fierz YC, Kenmeni R, Gonthier A, et al. Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient. Eur J Clin Nutr 2014; 68:531.
  114. Anand G, Schmid C. Severe hypophosphataemia after intravenous iron administration. BMJ Case Rep 2017; 2017.
  115. Huang LL, Lee D, Troster SM, et al. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrol Dial Transplant 2017.
  116. Derman R, Roman E, Modiano MR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol 2017; 92:286.
  117. Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant 2015; 30:1577.
  118. Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 2016; 31:646.
  119. Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 2013; 108:1877.
  120. Birgegård G, Henry D, Glaspy J, et al. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial. Pharmacotherapy 2016; 36:402.
  121. Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study. Vox Sang 2017; 112:122.
  122. Hildebrandt PR, Bruun Ne, Nielsen OW, et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. Transfus Altern Transfus Med 2010; 11:131.
  123. (Accessed on March 03, 2018).
  124. (Accessed on March 03, 2018).
  125. Winyard PG, Blake DR, Chirico S, et al. Mechanism of exacerbation of rheumatoid synovitis by total-dose iron-dextran infusion: in-vivo demonstration of iron-promoted oxidant stress. Lancet 1987; 1:69.
  126. Bircher AJ, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin N Am 2014; 34:707.
  127. Barton JC, Barton EH, Bertoli LF, et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 2000; 109:27.
  128. Wang C, Graham DJ, Kane RC, et al. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products. JAMA 2015; 314:2062.
  129. DeLoughery TG, Auerbach M. Is low-molecular weight iron dextran really the most risky iron?--Unconvincing data from an unconvincing study. Am J Hematol 2016; 91:451.
  130. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 2015; 90:12.
  131. Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010; 85:650.
  132. Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfusion Alternatives in Transfusion Medicine 2007; 9:8.
  133. Coyne DW, Adkinson NF, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003; 63:217.
  134. Santosh S, Podaralla P, Miller B. Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol. NDT Plus 2010; 3:341.
  135. Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm 2012; 69:310.
  136. Auerbach M, Kane RC. Caution in making inferences from FDA's Adverse Event Reporting System. Am J Health Syst Pharm 2012; 69:922.
  137. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007; 369:1502.
  138. Marx JJ. Iron and infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol 2002; 15:411.
  139. Torres S, Kuo YH, Morris K, et al. Intravenous iron following cardiac surgery does not increase the infection rate. Surg Infect (Larchmt) 2006; 7:361.
  140. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12:231.
  141. Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial. Accepted for publication. Am J Hematol 2013.
  142. Grasso P. Sarcoma after intramuscular iron injection. Br Med J 1973; 2:667.
  143. Greenberg G. Sarcoma after intramuscular iron injection. Br Med J 1976; 1:1508.
  144. Modepalli N, Shivakumar HN, McCrudden MT, et al. Transdermal Delivery of Iron Using Soluble Microneedles: Dermal Kinetics and Safety. J Pharm Sci 2016; 105:1196.
  145. Kitsati N, Liakos D, Ermeidi E, et al. Rapid elevation of transferrin saturation and serum hepcidin concentration in hemodialysis patients after intravenous iron infusion. Haematologica 2015; 100:e80.
  146. Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood 2014; 123:326.
  147. Hershko C, Hoffbrand AV, Keret D, et al. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica 2005; 90:585.
Topic 7148 Version 96.0